How to Get Repatha (Evolocumab) in Tennessee

What Repatha Is and Why Tennessee Patients Seek It

Repatha is a PCSK9 inhibitor. It works by blocking proprotein convertase subtilisin/kexin type 9, the enzyme that degrades LDL receptors on hepatocytes, allowing those receptors to remain active and pull more LDL cholesterol out of circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and primary hyperlipidemia, and in December 2017 expanded the label to include adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of MI, stroke, and coronary revascularization. [1]

The FOURIER trial (N=27,564) randomized patients with established ASCVD already on statin therapy to evolocumab or placebo. At a median follow-up of 2.2 years, evolocumab reduced LDL-C by 59% from baseline (from 92 mg/dL to 30 mg/dL) and cut the composite of cardiovascular death, MI, stroke, unstable angina, or coronary revascularization by a relative 15% (HR 0.85; 95% CI 0.79 to 0.92; P<0.001). [2]

Tennessee has above-average rates of cardiovascular mortality. The CDC reports that Tennessee's age-adjusted heart disease death rate is approximately 220 per 100,000 population, compared with a national rate near 180 per 100,000, which puts effective LDL-lowering squarely in the public health conversation for the state. [3]

Step 1: Confirm You Have a Qualifying Indication

Before scheduling any appointment, confirm that your clinical profile matches one of Repatha's FDA-approved indications. The two most common are heterozygous or homozygous familial hypercholesterolemia and established ASCVD with LDL-C that remains above guideline targets despite maximally tolerated statin and ezetimibe therapy.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol identifies a threshold for PCSK9 inhibitor consideration in very high-risk ASCVD patients as LDL-C persistently at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. [4] That same guideline states: "For patients with clinical ASCVD who are at very high risk and whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is recommended (Class I, LOE: A)."

For FH, the Familial Hypercholesterolemia Foundation recommends genetic testing or the Dutch Lipid Clinic Network criteria to confirm diagnosis before initiating specialty lipid therapy. An LDL-C above 190 mg/dL in an adult with a family history of premature heart disease is a reasonable screening flag.

Patients with LDL-C between 55 and 70 mg/dL who have had two or more major ASCVD events (for example, a second MI or ischemic stroke on top of established CAD) may also qualify under high-intensity statin guidelines, but insurers in Tennessee apply their own tier criteria.

Step 2: Get the Right Labs Before Your Appointment

Labs document medical necessity. Most Tennessee commercial plans require a current fasting lipid panel, typically drawn within the past 90 days, to process prior authorization.

Minimum lab work you should have ready:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• LFTs (ALT, AST) to establish statin tolerance at baseline
• TSH if LDL-C is unexpectedly elevated (to rule out hypothyroidism as secondary cause)
• HbA1c or fasting glucose if metabolic syndrome is suspected

Some prescribers also order an apolipoprotein B (apoB) level, which correlates closely with atherogenic particle burden and can strengthen the documentation for PA. The American Association of Clinical Endocrinology 2022 Dyslipidemia Guidelines list apoB below 65 mg/dL as the optimal target for very high-risk patients, a target that is often unachievable with statins alone. [5]

Lipoprotein(a) testing is not mandatory for a Repatha prescription, but an Lp(a) above 50 mg/dL (or above 125 nmol/L) identifies a subgroup with inherited cardiovascular risk that supports escalation beyond statin therapy. FOURIER subgroup data showed that patients in the highest Lp(a) quartile had the greatest absolute benefit from evolocumab. [6]

Step 3: Choose Your Prescriber Pathway in Tennessee

Tennessee law gives you several options for obtaining an evolocumab prescription.

In-person cardiologist or lipid specialist. This remains the most straightforward route for patients with complex ASCVD history. Vanderbilt University Medical Center, UT Medical Center in Knoxville, and Methodist Le Bonheur Healthcare in Memphis all run dedicated preventive cardiology or lipid clinics. Referral wait times typically run 4 to 10 weeks.

Primary care physician (MD or DO). Any licensed Tennessee physician can prescribe Repatha, and many family medicine and internal medicine physicians do so. PCPs are often faster to access than cardiologists for stable, uncomplicated FH cases.

Nurse practitioner (NP) or physician assistant (PA). Tennessee grants full prescriptive authority to licensed advanced practice registered nurses (APRNs) with a controlled-substance certificate and to physician assistants under collaborative practice agreements. Both can independently prescribe and manage evolocumab therapy. Tennessee Board of Nursing confirms NP prescriptive authority under TN Code Ann. 63-7-123. [7]

Telehealth. Tennessee explicitly permits prescribing through synchronous audio-video telehealth for established and new patient relationships under TN Code Ann. 63-1-155, as clarified by the Tennessee Medical Practice Board's 2022 guidance. [8] A telehealth visit covers the same clinical evaluation as an in-person visit: review of labs, history of statin therapy, current cardiovascular risk, and contraindications. HealthRX connects Tennessee residents with board-certified clinicians who can evaluate and, where appropriate, prescribe evolocumab without requiring an in-person visit. The telehealth option is particularly useful for patients in rural Middle Tennessee, the Upper Cumberland region, or the Appalachian Highlands, where cardiology access is limited.

One practical note: telehealth prescribers still submit prior authorization requests to your insurer, and they still need your lab work before prescribing. Having your most recent lipid panel available before the video visit shortens the process significantly.

Step 4: Understand Prior Authorization in Tennessee

Prior authorization is the main friction point. Every major Tennessee commercial insurer, including BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, and Aetna, requires PA before dispensing Repatha.

Typical PA documentation requirements:

1. Current LDL-C on maximally tolerated statin (usually two documented statin trials at different doses or from different statin classes)
2. Documentation of ezetimibe trial (10 mg/day for at least 90 days) or clinical reason for not using ezetimibe
3. ICD-10 diagnosis code confirming HeFH, HoFH, or ASCVD
4. Prescriber attestation that Repatha is medically necessary

The phrase "maximally tolerated statin" is interpreted strictly. If the chart shows no statin trial on record, most plans deny on first submission. Statin intolerance documentation should include at least two separate statin trials with documented myalgia, elevated CK, or hepatic side effects. The National Lipid Association defines statin intolerance as inability to tolerate two or more statins at any dose due to objectively verifiable adverse effects. [9]

Tennessee commercial plans routinely issue an initial denial even with adequate documentation. That initial denial triggers the appeals process, which most plans are required to resolve within 30 days for standard cases and 72 hours for urgent cases under Tennessee Insurance Code. Filing a peer-to-peer review call between your prescriber and the plan's medical director resolves a meaningful proportion of denials, in some reports reducing reversal time to under one week.

TennCare (Tennessee Medicaid) note: TennCare does not cover Repatha for FH or ASCVD indications as of the current 2025 formulary. Coverage is limited to specific Type 2 diabetes-related cardiovascular indications under certain managed care contracts. Patients on TennCare should ask their prescriber about the Amgen PCSK9 patient assistance program (Repatha SupportPlus), which provides drug at no cost for qualifying uninsured and underinsured patients.

Step 5: Pharmacy Options in Tennessee

Once prior authorization clears, Tennessee patients can access Repatha through several channels.

Specialty pharmacy. Repatha is classified as a specialty medication. Most major specialty pharmacies, including Accredo (which Cigna owns), CVS Specialty, and Walgreens Specialty, are licensed in Tennessee and ship directly to patient addresses using cold-chain packaging. Evolocumab must be refrigerated at 36 to 46 degrees Fahrenheit; if stored at room temperature (up to 77 degrees Fahrenheit), it must be used within 30 days.

503A compounding pharmacies. Tennessee permits licensed 503A compounding pharmacies to compound medications for individual patients with a valid patient-specific prescription. As of July 2025, evolocumab is not listed on the FDA's list of essentially-copied drugs prohibited from 503A compounding, so a licensed Tennessee 503A pharmacy may legally compound it for a specific patient under federal 503A guidelines. [10] However, compounded evolocumab does not carry the Amgen quality-control data from FOURIER or GLAGOV trials, and no compounded biologic PCSK9 inhibitor has been studied in outcomes trials. Prescribers and patients should weigh that distinction carefully.

Retail pharmacy. Most standard retail pharmacies do not stock Repatha in Tennessee because cold-chain inventory management is not routine for retail. You can request that a retail pharmacy order it, but specialty pharmacy fulfillment is faster and typically pre-coordinated with the insurer.

Transfer of an existing prescription. If you move to Tennessee from another state, Tennessee pharmacy law allows prescription transfers for non-controlled substances. You or your new Tennessee prescriber can request a transfer from an out-of-state specialty pharmacy to a Tennessee-licensed specialty pharmacy. The receiving pharmacy needs the original prescription number, prescribing physician's DEA number (for verification purposes), and your insurance information.

Step 6: Timing and What to Expect

The time from your first telehealth or in-person consult to receiving your first pen injector at home depends almost entirely on prior authorization speed.

• Consult and lab review: same day if labs are already available
• PA submission: 1 to 3 business days after the consult
• PA decision: 5 to 15 business days for standard review (commercial plans)
• Specialty pharmacy processing and shipping: 2 to 5 business days after PA approval

Total elapsed time: commonly 2 to 4 weeks for straightforward commercial cases. Complex cases with appeals can extend to 6 weeks or longer.

Once you have the drug, Repatha is self-administered as a subcutaneous injection using a prefilled SureClick autoinjector or a prefilled syringe. The 140 mg dose is given every two weeks. The 420 mg once-monthly dose uses three 140 mg injections given consecutively within 30 minutes, or the 420 mg single-dose Pushtronex on-body infusor. Injection site rotation (abdomen, thigh, upper arm) reduces local reactions.

LDL-C response appears within 2 weeks and is maximal by approximately 4 to 8 weeks. The prescriber will typically recheck the lipid panel at 4 to 8 weeks after the first dose to confirm response and adjust the plan if needed.

Monitoring and Long-Term Management

Evolocumab does not require routine safety monitoring beyond what is standard for cardiovascular patients. No renal dosing adjustments are required. Hepatic impairment above Child-Pugh B has not been studied, so caution applies.

The OSLER-1 and OSLER-2 open-label extension trials (combined N=4,465; median follow-up 11.1 months) showed LDL-C levels sustained at a mean of 48 mg/dL with evolocumab added to background statin therapy, with no meaningful increase in adverse event rates compared with standard of care. [11] Longer-term data from the FOURIER open-label extension (FOURIER-OLE) at a median of 5 years showed that earlier initiation of evolocumab was associated with greater absolute cardiovascular risk reduction, providing additional rationale for not delaying therapy during prolonged PA disputes.

Neurocognitive concerns raised by earlier PCSK9 inhibitor observational data were addressed directly in the EBBINGHAUS trial (N=1,204 from FOURIER), which found no significant difference between evolocumab and placebo on any domain of the Cambridge Neuropsychological Test Automated Battery at 19 months of follow-up. [12]

Dr. Marc Sabatine, principal investigator for FOURIER, stated in a 2017 NEJM commentary: "The magnitude of LDL lowering with evolocumab, combined with the cardiovascular event reduction, supports using PCSK9 inhibition as a second-line agent after statins for patients at very high cardiovascular risk."

Annual lipid panel checks are appropriate for most patients once at goal. If LDL-C rises back above target, the prescriber should rule out non-adherence, drug storage errors, and new secondary causes before assuming pharmacologic failure.

Cost and Patient Assistance Programs

The list price for Repatha in the United States is approximately $550 to $650 per month. After rebates and formulary negotiations, many commercially insured Tennessee patients pay $5 to $35 per month under Amgen's Repatha SupportPlus co-pay program, which is available to patients with commercial insurance whose plans cover the drug.

Patients with no insurance or whose insurer has denied coverage can apply to the Amgen Safety Net Foundation, which provides Repatha at no cost to qualifying applicants with household income at or below 500% of the federal poverty level.